At a glance
ClinicalIndex Comparison RecordPhase 2Terminated· 59 enrolled
Drug / intervention
AK119 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Phase Ib/II Study of AK119 and AK112 With or Without Chemotherapy in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment
In Brief
A Phase 2 clinical trial evaluating AK119, AK112, and 2 other interventions for NSCLC. Terminated early, enrolled 59 participants across 1 site.
Signals
Trial was terminated early
Detailed Summary
This is a phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 and AK112 With or Without Chemotherapy for NSCLC patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC
CountriesChina
Collaborators--
Timeline
Phase 2TerminatedFinished
2023202420252026
First PostedDec 2022
Enrollment StartFeb 2023
Primary CompletionFeb 2025
Study CompletionApr 2025
TodayJul 2026
First PostedDec 5, 2022
Enrollment StartFeb 10, 2023
Primary CompletionFeb 24, 2025
Study CompletionApr 15, 2025
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 3.6 years ago
Interventions
AK119drug
AK119 IV every 3 weeks.
AK112drug
AK112 IV every 3 weeks.
Pemetrexeddrug
Pemetrexed IV every 3 weeks.
Carboplatindrug
Carboplatin IV every 3 weeks.